保和丸於胰臟惡性腫瘤末期運用之病例探討

Treatment of Advanced Pancreatic Carcinoma Patients with Baohe Pills: A Case Report

胰臟惡性腫瘤的61 歲女性，分析其癌症末期死亡前318 天的就診用藥，接受中西醫合併治療共58 日，在病患腎絲球過濾率下降到69 的時候，服用39 天的保和丸共248 公克，腎絲球過濾率上升到96。顯示中西藥併用不但沒有腎臟毒性的交互作用，而且保和丸在胰臟癌末期可能具有保護腎絲球免於損害的保護作用，結論：胰臟惡性腫瘤末期的病患如果腸胃功能不好、食慾不振，保和丸為一安全可以搭配併服用的中藥方劑。

We would like to report for what TCM practitioners may experience as a 61-year-old female patient goes through the end stages of pancreatic cancer. The retrospective chart was reviewed and we found that she received 58-day traditional Chinese herbal products in 318-day medical record before her death. Interestingly, her estimated glomerular filtration rate (eGFR) was from 69 mL/ min/1.73 m2 to 96 mL/min/1.73 m2 after taking 248-gram of Baohe pills (totally 39 days). This result infers that Baohe pills might be a safe choice in treating gastrointestinal upset for pancreatic patient who were receiving nephrotoxic chemotherapeutic regimen.